A carregar...
Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance
The development of inhibitors for the tyrosine anaplastic lymphoma kinase (ALK) has advanced rapidly, driven by biology and medicinal chemistry. The first generation ALK inhibitor crizotinib was granted US FDA approval with only four years of preclinical and clinical testing. Although this drug offe...
Na minha lista:
| Publicado no: | Acta Pharm Sin B |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elsevier
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4629211/ https://ncbi.nlm.nih.gov/pubmed/26579422 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.apsb.2014.12.007 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|